Top Cited Articles
Acceptance rate:
23%
Impact Factor (JCR):
12.485
IF rank (Oncology):
25/245
IF rank (Immunology):
79/162
Citescore:
14.3
Total content views:
1.12 million
Top Cited Articles (Published 2021 - 2022)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Brahmer, Julie R.; Abu-Sbeih, Hamzah; Ascierto, Paolo Antonio; et al
10.1136/jitc-2021-002435
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Alzeibak, Razan; Mishchenko, Tatiana A.; Shilyagina, Natalia Y.; et al
10.1136/jitc-2020-002038
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
Demaria, Sandra; Guha, Chandan; Schoenfeld, Jonathan; et al
10.1136/jitc-2020-002038
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Nakamura, Takashi; Sato, Takanori; Endo, Rikito; Sasaki, Shun; et al
10.1136/jitc-2021-002852
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Nishikawa, Hiroyoshi; Koyama, Shohei
10.1136/jitc-2021-002591
Acute kidney injury in patients treated with immune checkpoint inhibitors
Gupta, Shruti; Short, Samuel A. P.; Sise, Meghan E.; Prosek, Jason M.; et al
10.1136/jitc-2021-003467
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Cortellini, Alessio; Di Maio, Massimo; Nigro, Olga; Leonetti, Alessandro; et al
10.1136/jitc-2021-002421
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Ferris, Robert L.; Spanos, William C.; Leidner, Rom; Goncalves, Anthony; et al
10.1136/jitc-2021-002568
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Liu, Chao; Liu, Ruiqi; Wang, Bojun; Lian, Jie; et al
10.1136/jitc-2020-001895
Rethinking immune checkpoint blockade: 'Beyond the T cell'
Liu, Xiuting; Hogg, Graham D.; DeNardo, David G.
10.1136/jitc-2020-001460
Severity of COVID-19 in patients with lung cancer: evidence and challenges
Passaro, Antonio; Bestvina, Christine; Velez, Maria Velez; et al
10.1136/jitc-2020-002266
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Yin, Zi; Yu, Min; Ma, Tingting; Zhang, Chuanzhao; Huang, Shanzhou; et al
10.1136/jitc-2020-001698
Safety and activity of the TGF beta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Melisi, Davide; Oh, Do-Youn; Hollebecque, Antoine; Calvo, Emiliano; et al
10.1136/jitc-2020-002068
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
Yang, Moran; Lu, Jiaqi; Zhang, Guodong; Wang, Yiying; et al
10.1136/jitc-2020-001136
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
Zeng, Dongqiang; Wu, Jiani; Luo, Huiyan; Li, Yong; et al
10.1136/jitc-2021-002467
Intratumoral CD103+CD8+T cells predict response to PD-L1 blockade
Banchereau, Romain; Chitre, Avantika S.; Scherl, Alexis; et al
10.1136/jitc-2020-002231
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
Ricciuti, Biagio; Jones, Greg; Severgnini, Mariano; et al
10.1136/jitc-2020-001504
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Mu, Wei; Jiang, Lei; Shi, Yu; Tunali, Ilke; et al
10.1136/jitc-2020-002118
Off-the-shelf V delta 1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
Makkouk, Amani; Yang, Xue (Cher); Barca, Taylor; et al
10.1136/jitc-2021-003441
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
Marcu, Ana; Bichmann, Leon; Kuchenbecker, Leon; Kowalewski, Daniel Johannes; et al
10.1136/jitc-2020-002071